What is CytomX Therapeutics, Inc.'s Shariah compliance score?

CytomX Therapeutics, Inc. (CTMX) has a Shariah compliance score of 71/100 (Grade: B+, Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does CytomX Therapeutics, Inc. pass AAOIFI screening?

CytomX Therapeutics, Inc. (CTMX) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (CTMX: 0.7%), (3) interest-bearing deposits below 30% (CTMX: 23.3%), and (4) prohibited income below 5% (CTMX: 1.9%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for CytomX Therapeutics, Inc. stock?

CytomX Therapeutics, Inc. (CTMX) has a non-permissible income ratio of 1.88%. Muslim investors should purify this percentage of any dividends received and capital gains realized from CTMX shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen CytomX Therapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for CytomX Therapeutics, Inc. (CTMX) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about CTMX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

CTMX: Is CytomX Therapeutics, Inc. Halal?

CytomX Therapeutics, Inc.

NASDAQHealthcareUS

$3.66

-1.08%

Market Cap: 588.6M

Compliance Status

Halal

Screened on Jul 15, 2026 · AAOIFI Standard 21

B+

Good

71Score

Is CytomX Therapeutics, Inc. (CTMX) halal? Halal. Based on AAOIFI screening, CytomX Therapeutics, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 71/100 (Grade: B+).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.7% of 30.0% limit

What this means for you

You can own CTMX

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purify 1.9% of your income from CTMX

That is about $1.90 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 15, 2026

Compliance History

Halalnow
since Jun 2026
Doubtful
until the change above
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track CTMX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is CytomX Therapeutics, Inc. (CTMX) halal to invest in?

Based on AAOIFI Standard 21 screening, CytomX Therapeutics, Inc. (CTMX) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did CytomX Therapeutics, Inc. get a B+ compliance rating?

CytomX Therapeutics, Inc. (CTMX) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.7% (limit 30%); interest-bearing deposits of 23.3% (limit 30%); prohibited income of 1.88% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change CytomX Therapeutics, Inc.'s Shariah verdict?

CytomX Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is CytomX Therapeutics, Inc. re-screened for Shariah compliance?

CytomX Therapeutics, Inc. (CTMX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.